Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
APRE Aprea Therapeutics	$1.70 -1.7%	$1.74	$1.41 ▼ $5.01	$9.40M	1.19	27,148 shs	44,024 shs
BTAI BioXcel Therapeutics	$2.02 +2.5%	$1.65	$1.17 ▼ $21.92	$12.24M	0.04	1.23 million shs	274,253 shs
EMIS Emisphere Technologies	$7.81	$7.81	$4.06 ▼ $9.16	N/A	N/A	N/A	N/A
OMER Omeros	$3.93 +7.7%	$3.61	$2.95 ▼ $13.60	$230.26M	2.16	740,104 shs	1.00 million shs
RAPT Rapt Therapeutics	$8.72 +3.1%	$7.89	$5.67 ▼ $30.60	$144.23M	-0.09	164,944 shs	38,798 shs

Options Trading Made Easy - Download Now

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
APRE Aprea Therapeutics	-1.73%	-1.73%	-10.05%	+7.59%	-58.64%
BTAI BioXcel Therapeutics	+2.54%	+6.32%	+29.49%	+10.99%	-89.57%
EMIS Emisphere Technologies	0.00%	0.00%	0.00%	0.00%	0.00%
OMER Omeros	+7.67%	+27.60%	+15.59%	-42.79%	-7.96%
RAPT Rapt Therapeutics	+3.07%	+6.86%	+4.81%	+27.13%	-68.22%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
APRE Aprea Therapeutics	2.9304 of 5 stars	3.5	3.0	0.0	0.0	2.7	0.8	1.3
BTAI BioXcel Therapeutics	4.1605 of 5 stars	3.3	2.0	0.0	4.5	3.1	1.7	0.6
EMIS Emisphere Technologies	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
OMER Omeros	3.5835 of 5 stars	3.4	0.0	0.0	4.4	1.7	1.7	0.6
RAPT Rapt Therapeutics	4.3665 of 5 stars	3.1	4.0	0.0	4.2	2.3	1.7	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
APRE Aprea Therapeutics	3.00	Buy	$15.50	811.76% Upside
BTAI BioXcel Therapeutics	2.67	Moderate Buy	$42.60	2,008.91% Upside
EMIS Emisphere Technologies	0.00	N/A	N/A	N/A
OMER Omeros	2.83	Moderate Buy	$18.00	358.02% Upside
RAPT Rapt Therapeutics	2.17	Hold	$19.80	127.06% Upside

Current Analyst Ratings Breakdown

Latest BTAI, APRE, OMER, RAPT, and EMIS Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/10/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$27.00
6/30/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00
6/27/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00
6/26/2025	APRE Aprea Therapeutics	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform	$11.00
6/10/2025	OMER Omeros	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$9.00
5/22/2025	RAPT Rapt Therapeutics	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$16.00 ➝ $8.00
5/22/2025	RAPT Rapt Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Upgrade	Strong-Buy	$48.00
5/16/2025	OMER Omeros	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Hold ➝ Hold
5/13/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00
5/7/2025	OMER Omeros	D. Boral Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$36.00 ➝ $36.00

(Data available from 7/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
APRE Aprea Therapeutics	$1.50M	6.27	N/A	N/A	$3.55 per share	0.48
BTAI BioXcel Therapeutics	$2.27M	5.39	N/A	N/A	($30.01) per share	-0.07
EMIS Emisphere Technologies	N/A	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	($3.15) per share	N/A
RAPT Rapt Therapeutics	$1.53M	94.27	N/A	N/A	$11.51 per share	0.76

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
APRE Aprea Therapeutics	-$12.96M	-$2.37	N/A	N/A	N/A	-1,095.02%	-68.39%	-55.74%	8/11/2025 (Estimated)
BTAI BioXcel Therapeutics	-$59.60M	-$13.55	N/A	N/A	N/A	-2,163.18%	N/A	-83.80%	8/5/2025 (Estimated)
EMIS Emisphere Technologies	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
OMER Omeros	-$156.82M	-$2.65	N/A	N/A	N/A	N/A	N/A	-59.68%	8/6/2025 (Estimated)
RAPT Rapt Therapeutics	-$129.87M	-$19.20	N/A	N/A	N/A	N/A	-81.47%	-70.24%	8/6/2025 (Estimated)

Latest BTAI, APRE, OMER, RAPT, and EMIS Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/11/2025	Q2 2025	APRE Aprea Therapeutics	-$0.77	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	OMER Omeros	-$0.46	N/A	N/A	N/A	$0.31 million	N/A
8/5/2025	Q2 2025	BTAI BioXcel Therapeutics	-$2.30	N/A	N/A	N/A	$0.21 million	N/A
5/15/2025	Q1 2025	OMER Omeros	-$0.60	-$0.65	-$0.05	-$0.58	$0.40 million	N/A
5/14/2025	Q1 2025	APRE Aprea Therapeutics	-$0.6543	-$0.66	-$0.0057	-$0.66	N/A	$0.16 million
5/12/2025	Q1 2025	BTAI BioXcel Therapeutics	-$2.72	-$1.50	+$1.22	-$1.50	$0.35 million	$0.17 million
5/8/2025	Q1 2025	RAPT Rapt Therapeutics	-$2.48	-$0.64	+$1.84	-$0.08	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
APRE Aprea Therapeutics	N/A	N/A	N/A	N/A	N/A
BTAI BioXcel Therapeutics	N/A	N/A	N/A	N/A	N/A
EMIS Emisphere Technologies	N/A	N/A	N/A	N/A	N/A
OMER Omeros	N/A	N/A	N/A	N/A	N/A
RAPT Rapt Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
APRE Aprea Therapeutics	N/A	5.90	5.90
BTAI BioXcel Therapeutics	N/A	1.48	1.45
EMIS Emisphere Technologies	N/A	N/A	N/A
OMER Omeros	N/A	1.16	1.16
RAPT Rapt Therapeutics	N/A	21.11	21.11

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
APRE Aprea Therapeutics	34.19%
BTAI BioXcel Therapeutics	30.68%
EMIS Emisphere Technologies	N/A
OMER Omeros	48.79%
RAPT Rapt Therapeutics	99.09%

Insider Ownership

Company	Insider Ownership
APRE Aprea Therapeutics	13.63%
BTAI BioXcel Therapeutics	21.20%
EMIS Emisphere Technologies	72.90%
OMER Omeros	12.90%
RAPT Rapt Therapeutics	6.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
APRE Aprea Therapeutics	7	5.53 million	4.78 million	No Data
BTAI BioXcel Therapeutics	90	6.06 million	4.77 million	Optionable
EMIS Emisphere Technologies	6	N/A	N/A	Not Optionable
OMER Omeros	210	58.59 million	51.04 million	Optionable
RAPT Rapt Therapeutics	80	16.54 million	15.45 million	Optionable

BTAI, APRE, OMER, RAPT, and EMIS Headlines

Recent News About These Companies

HC Wainwright Forecasts Lower Earnings for Rapt Therapeutics

1 hour ago | americanbankingnews.com

HC Wainwright Analysts Decrease Earnings Estimates for RAPT

July 14 at 2:23 AM | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Price Target Raised to $27.00

July 13 at 2:27 AM | americanbankingnews.com

HC Wainwright Forecasts Strong Price Appreciation for Rapt Therapeutics (NASDAQ:RAPT) Stock

July 10, 2025 | marketbeat.com

RAPT Therapeutics Inc.

July 5, 2025 | barrons.com

RAPT Therapeutics Inc Ordinary Shares - Morningstar

July 3, 2025 | morningstar.comM

Rapt Therapeutics (NASDAQ:RAPT) Given Average Rating of "Hold" by Analysts

June 28, 2025 | marketbeat.com

RAPT Therapeutics expands board with two new directors

June 25, 2025 | investing.com

RAPT Therapeutics Appoints Scott Braunstein, M.D. and Ashley Dombkowski, Ph.D. to Board of Directors - Nasdaq

June 25, 2025 | nasdaq.com

RAPT Therapeutics Names Two Industry Veterans to its Board of Directors

June 23, 2025 | globenewswire.com

Rapt Therapeutics (NASDAQ:RAPT) Lowered to Sell Rating by Wall Street Zen

June 21, 2025 | marketbeat.com

Rapt Therapeutics (NASDAQ:RAPT) Shares Gap Down - Time to Sell?

June 18, 2025 | marketbeat.com

Wall Street Analysts Predict a 282.65% Upside in Rapt Therapeutics (RAPT): Here's What You Should Know

June 18, 2025 | zacks.com

RAPT Finalizes Reverse Split Plan; 1-for-8 Ratio Effective June 16, 2025

June 15, 2025 | nasdaq.com

RAPT Therapeutics, Inc. Announces 1-for-8 Reverse Stock Split Effective June 16, 2025

June 15, 2025 | nasdaq.com

RAPT Therapeutics, Inc.: RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13, 2025 | finanznachrichten.de

RAPT Therapeutics Announces Effective Date for 1-for-8 Reverse Stock Split

June 13, 2025 | globenewswire.com

Clear Street initiates Rapt Therapeutics stock with buy rating

June 7, 2025 | uk.investing.com

Rapt Therapeutics Get A Bullish Recommendation On ‘Significant Opportunity’ For Allergy Drug Candidate: Retail Worries About Cash Position

June 6, 2025 | msn.com

Rapt Therapeutics cuts staff for 2nd time in under a year, continuing fallout from FDA hold

June 4, 2025 | fiercebiotech.comF

RAPT Therapeutics to Participate in Upcoming Investor Conferences

June 4, 2025 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

Why BigBear.ai Could Rally 100% and Catch Palantir Soon
By Gabriel Osorio-Mazilli | June 30, 2025
View Why BigBear.ai Could Rally 100% and Catch Palantir Soon
Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
By Chris Markoch | June 25, 2025
View Top 3 Bank Stocks to Watch as Fed Rate Cuts Loom
3 Cloud Software Leaders Positioned for AI Upside
By Chris Markoch | July 10, 2025
View 3 Cloud Software Leaders Positioned for AI Upside
Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?
By Leo Miller | June 28, 2025
View Broadcom’s Big VMware Update: A Threat to Public Cloud Giants?
GE Aerospace Turns Engines Into Long-Term Profits
By Jeffrey Neal Johnson | June 21, 2025
View GE Aerospace Turns Engines Into Long-Term Profits

BTAI, APRE, OMER, RAPT, and EMIS Company Descriptions

Aprea Therapeutics NASDAQ:APRE

$1.69 -0.04 (-2.08%)

As of 07/14/2025 04:00 PM Eastern

Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel synthetic lethality-based cancer therapeutics that targets DNA damage response pathways. Its lead product candidate is the ATRN-119 that is in Phase I clinical trials for treating advanced solid tumors. The company is also developing ATRN-1051 for the treatment of ovarian cancer; and APRE-DDRi for the treatment of advanced solid tumors. The company is headquartered in Doylestown, Pennsylvania.

BioXcel Therapeutics NASDAQ:BTAI

$2.02 +0.05 (+2.54%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$2.08 +0.06 (+2.97%)

As of 07/14/2025 07:55 PM Eastern

BioXcel Therapeutics, Inc., a commercial-stage biopharmaceutical company, engages in utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology. The company's drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. Its commercial product, IGALMI, a sublingual film formulation of dexmedetomidine for the acute treatment of agitation associated with schizophrenia or bipolar I or II disorder in adults. The company also continues to conduct clinical trials evaluating BXCL501 for the acute treatment of agitation in Alzheimer's disease patients, and for adjunctive treatment of patients with major depressive disorder, as well as in the community for agitation associated with bipolar disorders and schizophrenia. In addition, it is developing BXCL502 as a potential therapy for chronic agitation in dementia; and BXCL701, an investigational, orally innate immunity activator for the treatment of aggressive forms of prostate cancer, pancreatic cancer, and other solid and liquid tumors; BXCL503, a drug candidate to target apathy in dementia; and BXCL504, a drug candidate to target aggression in dementia. BioXcel Therapeutics, Inc. was incorporated in 2017 and is headquartered in New Haven, Connecticut.

Emisphere Technologies OTCMKTS:EMIS

$7.81 0.00 (0.00%)

As of 12/9/2020

Emisphere Technologies, Inc. operates as a commercial stage pharmaceutical and drug delivery company in the United States. The company offers oral Eligen B12 Rx, an oral formulation prescription medical food for use by B12 deficient individuals. It is also developing GLP-1, which is in Phase III clinical trial for the treatment of type 2 diabetes and related conditions. The company's preclinical programs focus on the development of oral formulations for the treatment of diabetes; and products in the areas of cardiovascular, appetite suppression, and pain, as well as in the development and expansion of nutritional supplement products. It has license agreements with Novo Nordisk A/S to develop and commercialize oral formulations of GLP-1 receptor agonists in combination with Emisphere carriers, as well as to develop and commercialize oral formulations of Novo Nordisk's insulin using the company's Eligen Technology. The company was formerly known as Clinical Technologies Associates, Inc. and changed its name to Emisphere Technologies, Inc. in 1991. Emisphere Technologies, Inc. was founded in 1986 and is based in Roseland, New Jersey.

Omeros NASDAQ:OMER

$3.93 +0.28 (+7.67%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$3.96 +0.03 (+0.76%)

As of 07/14/2025 07:58 PM Eastern

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19. It also develops OMS1029 that is in phase I clinical trials for long-acting second-generation antibody targeting lectin pathway disorders; OMS906 that has completed phase II clinical trials for Paroxysmal nocturnal hemoglobinuria, complement 3 glomerulopathy, and other alternative pathway disorders; and OMS527 that is in phase I clinical trials for addictions and compulsive disorders, and movement disorders. In addition, the company's products under preclinical development comprise MASP-2, a pro-inflammatory protein target for the treatment of lectin pathway disorders; MASP-3 small-molecule inhibitors for alternative pathway disorders; and Adoptive T-Cell and Chimeric Antigen Receptor (CAR) T-Cell Therapies and Immunomodulators/Immunotoxins/Cancer Vaccines for the treatment of various cancers. Omeros Corporation was incorporated in 1994 and is headquartered in Seattle, Washington.

Rapt Therapeutics NASDAQ:RAPT

$8.72 +0.26 (+3.07%)

Closing price 07/14/2025 04:00 PM Eastern

Extended Trading

$8.72 0.00 (0.00%)

As of 07/14/2025 05:40 PM Eastern

RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Its lead oncology drug candidate is tivumecirnon (FLX475), an oral small molecule CCR4 antagonist that is in the Phase 1/2 clinical trial to investigate as a monotherapy and in combination with pembrolizumab in patients with advanced cancer. The company was formerly known as FLX Bio, Inc. and changed its name to RAPT Therapeutics, Inc. in May 2019. RAPT Therapeutics, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California. RAPT Therapeutics, Inc. operates as a subsidiary of Bristol-Myers Squibb Company

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time